Marshall Wace’s Damora Therapeutics DMRA Stock Holding History

Marshall Wace’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-169,818	Closed	-$4.4M	–	3385
2026 Q1	$4.4M	Buy	+169,818	New	+$4.36M	﹤0.01%	1365

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Marshall Wace's DMRA Position: Q2 2026 in Review

Marshall Wace sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 169,818 shares — an estimated $4.4M sold.

Marshall Wace first reported a position in DMRA in Q1 2026 and held it in 1 quarter. The position peaked at $4.4M in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Marshall Wace reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 169,818 Damora Therapeutics shares in Q2 2026, an estimated $4.4M.
Marshall Wace first reported a position in Damora Therapeutics in Q1 2026 and held it in 1 quarter.
Marshall Wace's Damora Therapeutics position peaked at $4.4M in Q1 2026.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.